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Abstract
Background: The prevalence of undetected left ventricular diastolic dysfunction is high, especially in the elderly with
comorbidities. Left ventricular diastolic dysfunction is a prognostic indicator of heart failure, in particularly of heart
failure with preserved ejection fraction and of future cardiovascular and all-cause mortality. Therefore we aimed to
develop sex-specific diagnostic models to enable the early identification of men and women at high-risk of left ventricular
diastolic dysfunction with or without symptoms of heart failure who require more aggressive preventative strategies.
Design: Individual patient data from four primary care heart failure-screening studies were analysed (1371 participants,
excluding patients classified as heart failure and left ventricular ejection fraction <50%).
Methods: Eleven candidate predictors were entered into logistic regression models to be associated with the presence
of left ventricular diastolic dysfunction/heart failure with preserved ejection fraction in men and women separately.
Internal-external cross-validation was performed to develop and validate the models.
Results: Increased age and b-blocker therapy remained as predictors in both the models for men and women. The model
for men additionally consisted of increased body mass index, moderate to severe shortness of breath, increased pulse
pressure and history of ischaemic heart disease. The models performed moderately and similarly well in men (c-statistics
range 0.60–0.75) and women (c-statistics range 0.51–0.76) and the performance improved significantly following the add-
ition of N-terminal pro b-type natriuretic peptide (c-statistics range 0.61–0.80 in women and 0.68–0.80 in men).
Conclusions: We provide an easy-to-use screening tool for use in the community, which can improve the early
detection of left ventricular diastolic dysfunction/heart failure with preserved ejection fraction in high-risk men and
women and optimise tailoring of preventive interventions.
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Introduction
Left ventricular diastolic dysfunction (LVDD), a func-
tional cardiac abnormality, is characterised by the
impairment of left ventricular (LV) relaxation and
increased LV stiﬀness and is the dominant underlying
feature of heart failure with preserved ejection fraction
(HFpEF).
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The prevalence of undetected LVDD is high in
the community with estimates exceeding 30% in
population-based studies among adults.1,2 Recognising
LVDD is important as not only is it known to be inde-
pendently associated with the development of heart
failure (HF),3,4 but it is also known to be predictive
of cardiovascular and all-cause mortality.5,6 Therefore
early recognition and implementation of management
strategies could potentially play a major role in improv-
ing prognosis. To assess LVDD, the latest European
Society of Cardiology (ESC) guidelines suggest the
use of various structural/functional echocardiographic
measures including the left atrial volume index (LAVI),
E/e0 and longitudinal strain.6 However such measure-
ments are not feasible in all community-dwelling men
and women due to high costs and time pressures.
Currently, there are models available for the prediction
of all-type HF, highlighting the importance of history
taking and physical examination as well the use of N-
terminal pro b-type natriuretic peptide (NTproBNP).7
A practical model to predict LVDD (with or without
symptoms (HFpEF)) does not exist; previous studies
that examined predictors of LVDD lacked clinical vari-
ables and only included echocardiographic parameters,
and are therefore not applicable for use in the commu-
nity as a risk assessment tool to assess who should
undergo echocardiography or not.1,8
Previous HF-screening trials focused on a combin-
ation of high-risk patients from the community such as
the St Vincent’s Screening TO Prevent Heart Failure
(STOP-HF) trial which included participants with at
least one risk factor such as hypertension and hyperchol-
esterolemia.9 This trial demonstrated a reduction in
newly diagnosed HF and LV dysfunction (both diastolic
and systolic) following intervention with cooperative
cardiological management and intensiﬁed use of renin-
angiotensin blockers and b-blocker therapy. Therefore,
given the relevance of screening high-risk populations,
we aimed to develop and validate a risk prediction model
for LVDD/HFpEF using four HF-screening studies per-
formed in high-risk individuals from the community
aged 60 or 65 years and over. Given that evidence is
accumulating regarding determinants of LVDD/
HFpEF diﬀering according to sex, this was performed
separately for men and women. With this information,
preventative strategies within the community can be tai-
lored towards these high-risk individuals.
Methods
Study population
Four previously published studies performed in a pri-
mary care setting among high-risk community people
aged 60 or 65 years or older (STRETCH, TREE,
UHFO-COPD, and UHFO-DM) were combined into
one individual patient dataset (IPD).10–13 For a descrip-
tion of the four cohorts see Supplementary Material
Figure 1. All of these studies had a common aim to
screen for previously unknown, all-type HF. The studies
consisted of older people with either (a) symptoms of
shortness of breath on exertion,10 (b) multimorbidity or
polypharmacy,11 (c) chronic pulmonary obstructive dis-
ease (COPD),12 or type 2 diabetes (T2D).13 Data in all
cross-sectional diagnostic studies were collected from all
participants using the same uniform case record form
with questions regarding symptoms, drug use, medical
history, evaluation of physical signs, additional investiga-
tions with electrocardiography, B-type natriuretic peptide
testing and echocardiography.
Outcome, diagnostic predictors and model
development
The outcome of HF or no HF, was established by an
expert panel as described previously.10–13 In cases with
HF, the panel chose between HFpEF, heart failure with
reduced ejection fraction (HFrEF), and isolated right-
sided HF, primarily based on ejection fraction (cut-
point 45%) and estimated pulmonary artery pressures.
Natriuretic peptide measurements were used as an inclu-
sion criterion for echocardiography in the STRETCH
cohort, applying a cut-oﬀ point of NTproBNP level
above 125pg/ml (&15pmol/l).6 The panel also assessed
NTproBNP levels in the TREE cohort prior to diagnosis.
The panels were not privy to the NTproBNP levels in the
UHFO-COPD and UHFO-DM cohorts, thereby pre-
venting incorporation bias for this variable in these two
cohorts.14 The reproducibility of this panel consensus
method has been shown to be high (mean inter-agreement
with re-evaluation of a random sample of 10% of the
cases; K¼ 0.84 (Rutten K¼ 0.90, Mourik K¼ 0.74, van
Riet K¼ 0.89, Boonman K¼ 0.82)). Only patients who
underwent Tissue Doppler imaging (TDi) were selected
for the current study (Supplementary Material
Figure 1). All studies measured the early diastolic
lengthening velocities (e0) at the septal and lateral side
and took the average, except the UHFO-DM study
which only examined the septal side. We redeﬁned
patients with HF according to the recent 2016 ESC guide-
lines on HF into HFrEF, heart failure with midrange
ejection fraction (HFmrEF) and HFpEF using the cut-
points of left ventricular ejection fraction (LVEF) of 40%
and 50%. According to this deﬁnition, patients diagnosed
with HFrEF (n¼ 36, HF symptoms and LVEF <40%)
and HFmrEF (n¼ 52, HF symptoms LVEF 40–49%)
were removed, leaving 1371 patients in the current study.
Structural and functional abnormalities seen in
LVDD were assessed non-invasively by echocardiog-
raphy including measurements with TDi. LVDD was
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deﬁned in line with the recommendations from the 2012
and 2016 ESC guidelines on HF,6 and also published by
Paulus et al.15 as E/e0 above 13 or an E/e0 between 8–13
with at least one or more of the following:
– LAVI> 34ml/m2
– Left ventricular mass index (LVMI)> 115mg/m2 for
males or >95mg/m2 for females
– Atrial ﬁbrillation (AF) on the electrocardiogram
(ECG)
– NTproBNP level>125 pg/ml.
Those deﬁned as having LVDD, therefore, have a
LVEF 50% and contain asymptomatic participants
as well as individuals with HF symptoms and thus
may also be identiﬁed as HFpEF. The outcome was
subsequently deﬁned as those who fulﬁlled the criteria
for LVDD (including those with symptoms of HF and
thus HFpEF according to an expert panel) versus those
without LVDD (and in view of the exclusion criteria)
without LVSD/HFrEF/HFmrEF).
We evaluated, in a multivariable manner, 11 poten-
tial diagnostic predictors from previous literature,
known to predict, at least univariably, diastolic
dysfunction.1,5,8,16,17 These were; age, a history of
ischaemic heart disease (IHD), AF, hypertension,
T2D, angina pectoris, shortness of breath at least
when walking at a normal pace (MRC 3), ankle
oedema, pulse pressure, body mass index (BMI), and
the use of b-blocker therapy.
Data analysis
We aimed to derive four diagnostic models: ﬁrst, a clin-
ical model for men and women separately with all the
aforementioned variables and excluding NTproBNP,
and a second, extended model, again separately for
men and women, including all independent variables
with the addition of NTproBNP. From the candidate
diagnostic predictors, we selected those that were import-
ant in predicting the presence of LVDD/HFpEF in men
and women separately following the Akaike information
criteria (AIC) in a multivariable logistic regression
model. NTproBNP was log-transformed for all analyses.
A summary of the missing values is displayed in
Supplementary Material Table 2. Missing values in
each dataset set were imputed ﬁve times separately for
men and women using the MICE algorithm in R.18
In all analyses a linear relationship between the out-
come LVDD/HFpEF and the continuous predictors
age, BMI and log NTproBNP value was assumed and
checked. There was no collinearity between variables.
Data was analysed using R version 3.3.2.19
The internal-external cross validation (IECV)
method was used for model development and
validation. This method was recently recommended
by Steyerberg and Harrell for use when combining indi-
vidual patient data from multiple studies.20 Further
details can be found in the Supplementary Material.
The performance of the models was quantiﬁed by
examining discrimination and calibration.
A risk score was constructed for both men and
women separately from the ﬁnal models, multiplying
the shrunken coeﬃcients by two and then rounding to
the nearest integer. A dummy variable was added rep-
resenting whether a participant came from the TREE
cohort, the highest risk population, i.e. with three or
more chronic or vitality threatening diseases and/or
using ﬁve or more prescribed drugs daily during the
past year in people aged 65 years, to account for dif-
ferences in prevalence and therefore baseline risk of
LVDD/HFpEF. The risk of LVDD/HFpEF was then
calibrated using logistic regression modelling according
to the scores, resulting in a corresponding risk for each
score, which was presented graphically. The total range
of scores was divided by three to create diﬀerent risk
groups; mild, moderate and high. The participants were
then allocated a particular group depending on their
summed score.
Results
The baseline characteristics of the 1371 patients
included in the study from the four participating
cohorts stratiﬁed by sex are displayed in Table 1.
Overall more women (n¼ 706, 51.5%) than men
(n¼ 665, 48.5%) participated in the studies. Mean age
was comparable across the four cohorts (range
71.0–75.5 years), although somewhat lower in the
UHFO-DM cohort because of the age cut-point of
60 years, and there were no mean age diﬀerences
between sexes within each cohort. BMI was generally
higher in women (mean BMI 28.2 (standard deviation
4.9)) than in men (27.2 (standard deviation 3.7)) across
all cohorts. Women were more likely to suﬀer from
hypertension (67.4% vs 56.4%), whereas men were
more likely to suﬀer from T2D than women (23.4%
vs 18.4%) in the three cohorts excluding UHFO-DM
(as all participants have T2D). Men were also more
likely to suﬀer from IHD (21.1% vs 7.4%), and more
often had a history of AF (11.6% vs 4.4%) than
women. The prevalence of previously unrecognised
LVDD/HFpEF was higher in women than men
(72.2% vs 55.6%) (Table 1).
From the 11 candidate predictors in the clinical
model, age and b-blocker therapy were important pre-
dictors in a minimum of three out of the four datasets
for the presence of LVDD/HFpEF in women (Table 2).
In men, increased age, increased BMI, shortness of
breath when walking at a normal pace or worse
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(MRC 3), increased pulse pressure, a history of IHD
and also b-blocker therapy were important predictors
in a minimum of three out of the four datasets. Beta
coeﬃcients and odds ratios (ORs) for each of the ﬁnal
predictors for men and women were additionally calcu-
lated for only the individuals with NTproBNP levels
>125 pg/ml (Supplementary Material Table 3).
Discrimination of the models was similar between
men and women. Discrimination of the male model
(consisting of increased age, increased BMI, shortness
of breath when walking at a normal pace or worse
(MRC 3), increased pulse pressure, a history of
IHD and b-blocker therapy) ranged at cross-validation
from area under the curve (AUC) 0.60–0.75
(Supplementary Material Table 4). Discrimination of
the female model (consisting of only age and b-blocker
therapy) ranged at cross-validation from AUC
0.51–0.76. The addition of NTproBNP to the models
improved the performance in both men and women
with AUCs in men ranging from 0.68–0.80 and in
women from 0.61–0.80. Calibration of the models, as
displayed by the observed/expected (OE) ratios
(Supplementary Material Table 4) and visualised with
calibration plots (Supplementary Material Figure 2)
was better in women than men but improved in both
men and women following the addition of NTproBNP
to the models.
The corresponding bootstrap corrected c-statistic of
the ﬁnal model for all four cohorts combined in men
was 0.66 (95% conﬁdence interval (CI) 0.62–0.69) for
the clinical model and 0.80 (95% CI 0.77–0.84) for the
extended model with the addition of NTproBNP. For
women, the corresponding bootstrap corrected c-statis-
tic of the ﬁnal model was 0.58 (95% CI 0.54–0.62) for
the clinical model and 0.78 (95% CI 0.74–0.81) for the
extended model with the addition of NTproBNP.
From these ﬁnal models, a scoring rule was con-
structed, separately for men and women with and with-
out NTproBNP (Table 3). This scoring rule can be used
to extrapolate the absolute risk of an individual having
LVDD/HFpEF by ﬁrst summing up the score and then
applying it to the predicted probability ﬁgures repre-
sented in Supplementary Material Figures 3 and 4.
The performance of the female model using the add-
itional male speciﬁc predictors in addition to age and b-
blocker therapy (increased BMI, shortness of breath
when walking at a normal pace or worse (MRC 3),
increased pulse pressure, a history of IHD), as assessed
by the bootstrap corrected c-statistic was 0.60 (95% CI
0.56–0.63) and with the addition of NTproBNP 0.78
(95% CI 0.74–0.81). Hence adding the additional pre-
dictors did not improve the performance signiﬁcantly.
The performance of male model using only the pre-
dictors remaining in the female model which were
also present in the male model (age and b-blocker
therapy) i.e. excluding the additional male-speciﬁc pre-
dictors, was 0.62 (95% CI 0.59–0.66) and with the add-
ition of NTproBNP 0.80 (95% CI 0.76–0.83).
Using the risk scores to categorise men and women
into low, moderate and high-risk categories (Figure 1),
we show that with a cut-point of 22 or above, 34.7% of
men are at high-risk of having LVDD/HFEF and thus
should undergo echocardiography. Of these men,
88.8% will actually have conﬁrmed LVDD/HFpEF.
With a cut-point of above 14, 21.4% of women are
categorised as being at high-risk of having LVDD/
HFpEF, so should also undergo echocardiography.
Of these women, 97.4% will have conﬁrmed LVDD/
HFpEF.
Discussion
We developed and validated the ﬁrst sex-speciﬁc models
for the prediction of LVDD/HFpEF among high-risk
men and women over the age of 60 or 65 in four oppor-
tunistic HF screening cohorts in the community. The
multivariable logistic models performed similarly in
men and women and both sexes shared overlapping
predictors, albeit with the model in women only con-
taining two of the six independent predictors making
up the male model (increased age and b-blocker ther-
apy). The male model also consisted of history of IHD,
shortness of breath when walking at a normal pace or
worse (MRC 3), increased pulse pressure and
increased BMI. Nevertheless, after applying the male
model in females and visa versa, it is evident that age,
b-blocker therapy and NTproBNP are the most
important predictors in both men and women for
predicting LVDD/HFpEF. The model accurately
categorises 88.3% of high-risk men and 94.4% of
high-risk women, according to the constructed
risk scores, as having conﬁrmed LVDD/HFpEF on
echocardiography.
Age is a well-known determinant of LVDD/HFpEF
and also of all-type HF,16 being previously found to be
a predictor of all-type HF in the community using the
same four community cohorts used in this study.21
Echocardiographic parameters used to deﬁne LVDD
are aﬀected by the eﬀect of ageing on myocardial stiﬀ-
ness.22 Also, increased BMI and IHD have previously
been shown to be independent predictors of
LVDD.23,24 Interestingly, we showed that these vari-
ables remained as independent predictors in a reduced
model with backward regression only in men. b-Blocker
therapy remained an independent predictor in both
men and women. We subsequently evaluated a model
containing only hypertension, angina, AF, history of
IHD, as possible indications for b-blocker therapy use
in addition to b-blocker therapy, and still showed an
independent association between b-blocker therapy and
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LVDD/HFpEF in both men (OR 2.45 (95% CI 1.64–
3.66)) and women (OR 1.74 (95% CI 1.14–2.64)),
although these values were lower than with univariable
analysis (OR 3.32 (95% CI 2.33–4.75) in men, OR 2.17
(95% CI 1.48–3.18) in women). However, whether the
use of b-blockers is related to LVDD/HFpEF or their
use is merely representative of the many indications
including a history of IHD, angina pectoris, AF and
other tachycardias, and hypertension, remains unclear.
The addition of NTproBNP to the models signiﬁ-
cantly improved the performance of the models in
both men and women. This highlights the importance
of NTproBNP, not only in diagnosing HFpEF but also
for LVDD and, as previously shown, for all-type HF.6,7
We present the ﬁrst models of their kind. We have
previously presented a model to identify high-risk men
and women of having all-type HF in the same studied
community.21 However this and other screening studies
have not looked at LVDD/HFpEF in men and women
separately from the community. Previous models also
lacked external validation and incorporated echocar-
diographic parameters into the models and thus,
because of logistic reasons and the costs involved,
cannot be used in the community.1,8 A study by Ho
et al. compared the prediction of HFrEF and HFpEF
and found that increased age, increased BMI, antihy-
pertensive treatment, and IHD were independent pre-
dictors of HFpEF in multivariable analyses in four
combined general population studies.17 Increased age,
sex, increased systolic blood pressure, increased BMI,
smoking status, antihypertensive treatment, LV hyper-
trophy, left bundle branch block, T2D, and previous
Table 3. Clinical scoring rule for (a) men and (b) women with and without N-terminal pro b-type natriuretic peptide (NTproBNP).
(a) Rule score A: summation of points including NTproBNP Points
Age (per 10 years) 1
History of ischaemic heart disease 1
Dyspnoea (MRC3) 1
BMI (per 5 kg/m2) 1
Pulse pressure (per increase of 20) 1
b-Blocker therapy 1
High-risk because of multimorbidity and polypharmacya 4
NTproBNP in pg/ml per 100 pg/ml 2
Rule score B: summation of points excluding NTproBNP
Age (per 10 years) 2
History of ischaemic heart disease 1
Dyspnoea (MRC 3) 1
BMI (per 5 kg/m2) 1
Pulse pressure (per increase of 20) 1
b-Blocker therapy 1
High-risk because of multimorbidity and polypharmacya 4
(b) Rule score A: summation of points including NTproBNP
Age (per 10 years) 1
b-Blocker therapy 1
High-risk because of multimorbidity and polypharmacya 3
NTproBNP in pg/ml per 100 pg/ml 2
Rule score B: summation of points excluding NTproBNP
Age (per 10 years) 2
b-Blocker therapy 1
High-risk because of multimorbidity and polypharmacya 2
MRC: Medical Research Council; BMI: body mass index: HFpEF: heart failure with preserved ejection fraction; LVDD: left ventricular diastolic
dysfunction.
Use of the clinical scoring rule: for example, a 70-year-old woman (14 points), with a history of ischaemic heart disease, type 2 diabetes and
hypertension (two points for being high-risk) who is taking a b-blocker (one point), has a score of 17 points. According to Supplementary Material
Figure 4(b) this score corresponds to a risk of LVDD/HFpEF of approximately 85%. According to Figure 1b(ii), if a GP decided that all high-risk
individuals should be referred for echocardiography, the positive predictive value is 89.1%.
aMultimorbidity and polypharmacy is defined as having three or more chronic or vitality threatening diseases and/or using five or more prescribed drugs
daily during the past year in people aged 65 years
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myocardial infarction were predictive of HFrEF. It is
not known how the antihypertensive treatment was
deﬁned and whether or not it included b-blocker
therapy. They applied 45% as a cut-point between
HFrEF and HFpEF, thus not considering HFmrEF.
Although not clear, the authors may have analysed
HFpEF vs no HF plus HFrEF, and HFrEF vs no
HF plus HFpEF. It is important to highlight that we
evaluated LVDD/HFpEF vs no LVDD/HFpEF in a
population excluding LVSD/HFrEF and HFmrEF.
Despite the diﬀerences in methodology, the results of
the study by Ho et al. do show an overlap with our
results concerning antihypertensive treatment as an
independent predictor of LVDD/HFpEF in both men
and women.
Community cohorts provide a wealth of patient infor-
mation. Increasing the number of health care checks in
primary care, taking into account any barriers in the way
of patient access, can help identify men and women at
risk of developing diseases such as LVDD/HFpEF.25
With applying state-of-the art regression analysis we pre-
sent models that have been externally validated repre-
senting the ‘real world’ population as our cohorts
involve older men and women from the community
who have a variety of diﬀerent risk proﬁles, which is
representative of the patients attending general
(a) (i)
Summed 
score 
from 
scoring 
rule
Probability 
of HF
estimated 
by the 
scoring 
rule
Percentage 
of 
participants
Sensitivity Specificity Positive 
predictive value
Negative 
predictive 
value
16 <12% 9.0% 0.99 0.19 60.5 98.9 
17 <19% 18.1% 0.97 0.37 65.7 96.8 
18 <38% 28.9% 0.91 0.54 71.3 91.1 
20 <49% 47.8% 0.78 0.80 82.7 77.6 
22 <69% 65.3% 0.55 0.91 88.3 55.1 
Number ofScore range Risk 
participants 
(%) 
Number of 
patients with 
LVDD/HFpEF 
present (%) 
120 ≤17Low 
(18.1%) 
12 (0.1) 
314 18–21 Moderate 
(47.2%) 
154 (49.0) 
231 ≥22High 
(34.7%) 
204 (88.3) 
(a) (ii)
Summed 
score 
from 
scoring 
rule
Probability 
of HF
estimated 
by the 
scoring 
rule
Percentage 
of 
participants
Sensitivity Specificity Positive 
predictive value
Negative 
predictive 
value
22 <19% 11.6% 0.97 0.22 60.9 96.8 
23 <31% 24.4% 0.91 0.43 66.8 90.8 
24 <49% 37.6% 0.80 0.60 71.3 80.0 
26 <62% 63.0% 0.55 0.85 82.5 54.9 
28 <82% 81.4% 0.30 0.95 88.7 29.7 
Number of Score range Risk 
participants 
(%) 
Number of 
patients with 
LVDD/HFpEF 
present (%) 
162 <24 Low 
(24.4%) 
34 (21.0) 
379 24–27 Moderate 
(57.0%) 
226 (59.6) 
124 ≥28High 
(18.6%) 
110 (88.7) 
Figure 1. Application of the clinical prediction rule for (a) men and (b) women with (i) and without (ii) N-terminal pro b-type
natriuretic peptide (NTproBNP). HF: heart failure; HFpEF: heart failure with preserved ejection fraction; LVDD: left ventricular
diastolic dysfunction.
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practitioner clinics at high-risk of LVDD/HFpEF. Once
patients have been identiﬁed at risk of having LVDD,
management including treatment and preventative stra-
tegies can be implemented such as risk factor manage-
ment such as adequate management of diabetes,
hypertension and cardiac ischaemia, as recommended
by the guidelines to prevent progression of the disease
and to prevent LVDD from entering into the symptom-
atic phase, i.e. HFpEF.6 These models can also be used
to help identify low risk patients who do not require
echocardiography limiting unnecessary cardiology and
echocardiography referrals, reducing health-care costs
and reducing demands on resources. Treatment with
spironolactone has shown promise in reducing cardio-
vascular events in patients with HFpEF in the
Treatment of Preserved Cardiac Function Heart
Failure with an Aldosterone Antagonist (TOPCAT)
trial post-hoc analysis results of the American sub-set
population, and in those with elevated natriuretic pep-
tide levels.26,27 Thus, it is not only extremely helpful in
relieving symptoms in these patients suﬀering from con-
gestion, which is one of the primary goals of such
patients, but it may also help improve outcomes. Other
drugs such as empagliﬂozin show potential but the eﬀect
on cardiovascular outcomes will be determined in the
near future following results of clinical trials. Therefore
our models will be able to identify patients who would
beneﬁt from not only risk factor control and symptom-
atic relief with diuretics, but will also improve morbidity
and prognosis of these patients.28
Strengths and limitations
Our study consists of cohorts from the general population
and are applicable to primary care settings. By excluding
LVSD/HFmrEF/HFrEF instead of combining them with
(b) (i)
Summed 
score 
from 
scoring 
rule
Probability 
of HF
estimated 
by the 
scoring 
rule
Percentage 
of 
participants
Sensitivity Specificity Positive 
predictive value
Negative 
predictive 
value
8 <38% 11.6% 0.95 0.30 78.0 95.5 
9 <51% 22.8% 0.88 0.51 82.4 88.0 
10 <56% 36.0% 0.78 0.72 87.8 77.8 
12 <79% 61.3% 0.50 0.90 92.7 49.6 
14 <70% 78.6% 0.29 0.98 97.4 28.8 
Number of Score range Risk 
participants 
(%) 
Number of 
patients with 
LVDD/HFpEF 
present (%) 
161 <9 Low 
(22.8%) 
61 (37.9) 
394 9–14 Moderate 
(55.8%) 
302 (76.6) 
151 >14 High 
(21.4%) 
147 (97.4) 
(b) (ii)
Summed 
score from 
scoring 
rule
Probability of 
LVDD/HFpEF
estimated by 
the scoring 
rule
Percentage 
of 
participants
Sensitivity Specificity Positive 
predictive 
value
Negative 
predictive 
value
12.5 <31% 2.8% 0.99 0.08 73.8 99.2 
13 <36% 7.4% 0.96 0.16 74.8 95.9 
13.5 <56% 16.3% 0.90 0.33 77.8 90.2 
14 <58% 23.9% 0.85 0.46 80.3 84.5 
16 <76% 59.6% 0.50 0.84 89.1 49.8 
Risk Score range Number of 
participants (%) 
Number of 
patients with 
LVDD/HFpEF 
present (%) 
21 (40.4) 52 (7.4%) <13 Low 
235 (63.7) 369 (52.2%) 13–16 Moderate 
254 (89.1) 285 (40.4%) >16 High 
Figure 1. Continued.
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no HF we provide better predictions as we are able to
discriminate between subjects with HFpEF and no HF.
However an outcome ideally consisting of three cate-
gories; no HF, HFrEF and HFmrEF, and HFpEF
would likely lead to a more informed clinical applicabil-
ity. A limitation of our study is that participants of the
STRETCH study only underwent echocardiography
examination if they had an abnormal ECG and/or an
NTproBNP >125pg/ml. This criterion may have resulted
in missing some participants with LVDD/HFpEF that
were erroneously considered to have no structural or
functional cardiac abnormalities. The prevalence estimate
in that study may therefore be a little bit too high, but this
is unlikely to aﬀect the modelling and the related ORs,
especially not when combining this study with the other
three studies without such an exclusion criterion. Another
limitation is that E/e0 was used to diagnose diastolic dys-
function although evidence backing up the use of resting
E/e0 for left ventricular ﬁlling pressure remains limited.29
Incorporation bias has been mentioned previously, as the
expert panel on two out of the four cohorts were aware of
the NTproBNP results when deciding on the diagnosis. It
is important to realise that incorporation bias is inevitable
in diagnostic modelling studies.14 However, avoiding the
use of the NTproBNP results in the panel diagnosis may
lead to a worse problem; misclassiﬁcation of patients.14 It
is also important to note that in our study the informa-
tion obtained from echocardiography was not used in the
formulation of the prediction models. Trials previously
focusing on at-risk cohorts, such as the STOP-HF trial
have found a reduction in HF onset therefore our high-
risk cohorts provide a valid basis to screen for HF/
LVDD. However, it is important to note that translation
of such risk management strategies into routine primary
care practices may be challenging.
In summary, we developed and externally validated
sex-speciﬁc models for the prediction of LVDD/
HFpEF in community-based high-risk older men and
women. This unique early detection model will help to
optimise tailoring of the required preventative interven-
tions for LVDD/HFpEF.
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